

Publicly Funded RSV Vaccine for Long-Term Care and Personal Care Home Residents

Residents aged 60 years and older are now eligible to receive the Respiratory Syncytial Virus (RSV) vaccine at no cost.

Effective August 24, 2026:

- Long-term care (LTC) and personal care home (PCH) residents who are 60 years and older **and who have never** received an RSV vaccine dose at any age **are eligible** to receive **one publicly funded dose of RSV vaccine**.
- LTC and PCH residents who are younger than 60 years old, **and** residents 60 years and older **who have** previously received an RSV vaccine at any age, **are ineligible for publicly funded RSV vaccine**.

Additional Information:

- Abrysvo® and Arexvy® RSV vaccines are publicly funded for eligible LTC and PCH residents in 2026-27.
- For 2026-27, the Ministry of Health will distribute publicly funded Abrysvo® **and/or** Arexvy® vaccine doses exclusively through public health offices for administration **only** in LTC and PCH facilities. **Distribution to other healthcare providers will not occur this year.**
- The [RSV vaccine fact sheet](#) will be posted soon and must be provided to individuals as part of the informed consent process.
- RSV vaccine information will be added to the [Saskatchewan Immunization Manual Chapter 10](#) soon.

Please share this bulletin with your staff and colleagues.

Population Health Branch, Information Bulletin No. 6, August 4, 2026